Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections

Table 1

Data on previous vancomycin/daptomycin therapy in MRSA and MSSA clinical isolates non-susceptible to daptomycin.

Strain	Infection	Previous VAN therapy (days)	Reason for change	DAP therapy	MIC of DNS strain (days*)	Outcome	Ref.
MRSA	IE	Yes (No data)	Failure	Yes	MIC 2^b (No data)	No data	[26] (Case report)
MRSA	IE	Yes (47**)	Failure	Yes	MIC 4^a(14)	Died (C. albicans septic shock)	[27] (Case report)
MRSA	IE	Yes (46***)	Failure	6 mg/kg q24 h	MIC 4^a (24)	Survived on alternative treatment	[30] (Case report)
MRSA	BSI	Yes (15)	Failure	6 mg/kg q24 h, then 8 mg/kg q24 h	MIC 4^a (6)	Died	[31] (Case report)
MRSA	BSI	Yes (No data)	No change	No	MIC 2^a (No data)	No data	[32] (Case series)
MRSA	UTI	Yes (12)	Failure	6 mg/kg q24 h	MIC 4^a (7)	Died	[29] (Case report)
MSSA	OM	Yes (60)	Failure	No	MIC 4^a(No data)	Survived on alternative treatment(nafcillin +rifampin)	[34] (Case report)

DAP: daptomycin; VAN: vancomycin; DNS: daptomycin non-susceptible; UTI: urinary tract infection; BSI: bloodstream infection; IE: infective endocarditis; OM: osteomyelitis. MRSA: meticillin-resistant S. aureus; MSSA: meticillin-susceptible S. aureus; *duration (days) of treatment with daptomycin prior to isolate was obtained; **vancomycin for 12 days, then teicoplanin 35 days; ***2 courses: 6 weeks initially, additional 4 days after relapse; (a) broth microdilution (b) Etest. All initial isolates were susceptible to daptomycin; MIC: minimal inhibitory concentration (mg/L).